focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Japan's Suga urges citizens to have a quiet and distanced New Year

Fri, 25th Dec 2020 04:37

(Updates with reports on first cases of mutated coronavirus)

By Kiyoshi Takenaka and Tetsushi Kajimoto

TOKYO, Dec 25 (Reuters) - Japanese Prime Minister Yoshihide
Suga urged the nation on Friday to spend a quiet New Year period
without the usual social gatherings to prevent the spread of
COVID-19, which has been breaking infection records almost on a
daily basis.

Suga also announced a package of $2.6 billion for hospitals
treating COVID-19 patients which have come under strain due to
the rapid rise in cases across the northern island of Hokkaido
as well as large cities like Tokyo and Osaka.

"I want you to spend a quiet New Year," the premier told a
news conference in Tokyo with the government's leading
coronavirus expert Shigeru Omi.

"The infections aren't coming down and if we keep going like
this, we won't be able to avoid further spread of the virus."

The country confirmed its first cases of the new, faster-
spreading variant of the virus, in two citizens who had arrived
from the United Kingdom, domestic media reported late on Friday.

Japan has banned entry from United Kingdom, with the
exception of returning Japanese nationals and those with
residence permits.

Japan does not celebrate Christmas, but the New Year period
is an extended national holiday, with many people usually
travelling back to their hometowns and spending time with family
and friends.

Omi warned that it was critical that "all citizens move in
the same direction," to get a grip on the health crisis.

"If we don't bring infections down now, once they surge
again after the New Year period it won't be easy to change the
downward trend," he said. "It would take time, and would
probably be impossible to control over a period of weeks," he
said.

Omi said shared meals were a major cause of infections and
called on people to refrain from holding large gatherings and to
limit meals to four people one regularly ate with, or fewer.

While Japan has avoided the huge infection numbers seen in
other parts of the world, the number of new daily cases
surpassed 3,000 for the first time this month. Tokyo reported
884 infections on Friday, near Thursday's record 888.

HOSPITALS, VACCINES

Underscoring the strain on the hospitals, five national
groups of doctors and other medical workers made an emergency
request to Suga on Friday, asking for strong anti-pandemic
measures and support for the medical sector.

With hospitals equipped for treating COVID-19 filling up,
other hospitals are being forced to accept patients with the
disease, according to Tsuyoshi Masuda, president of the Japan
Federation of Democratic Medical Institutions.

"These small and medium-sized hospitals, which have been
supporting medical services in their respective regions, are
facing a crisis that is threatening their survival," Masuda told
reporters at a separate news conference on Friday.

He also warned that the risk of in-hospital infections was
high at institutions not specialized in dealing with infectious
diseases.

Japan, with a population of 126 million, has struck deals
to buy 290 million vaccine doses from Pfizer Inc,
AstraZeneca Plc and Moderna Inc, or enough for
145 million people.

A health ministry panel said that people aged 65 or older
should get priority for vaccination against COVID-19, as well as
frontline healthcare workers and people with underlying medical
conditions.

It specified chronic heart disease, chronic respiratory
disease and chronic kidney disease, among others, as underlying
conditions that should determine priority.

The panel's recommendations would mean 36 million elderly
people and 8.2 million people with medical conditions would be
the first to receive shots.
(Reporting by Kiyoshi Takenaka, Ju-min Park, Testsushi Kajimoto
and Antoni Slodkowski; Editing by Shri Navaratnam, Edmund
Klamann and William Mallard)

More News
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.